Belite Bio, Inc (BLTE)
| Market Cap | 6.43B +166.3% |
| Revenue (ttm) | n/a |
| Net Income | -102.36M |
| EPS | -2.74 |
| Shares Out | 40.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 184,762 |
| Open | 163.50 |
| Previous Close | 162.98 |
| Day's Range | 159.00 - 164.60 |
| 52-Week Range | 70.80 - 200.00 |
| Beta | -1.23 |
| Analysts | Strong Buy |
| Price Target | 228.89 (+43.45%) |
| Est. Earnings | Nov 9, 2026 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $228.89, which is an increase of 43.45% from the latest price.
News
Belite Bio management to meet with Piper Sandler
Meeting to be held in New Orleans on October 9 hosted by Piper Sandler.
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Tinlarebant's efficacy in Stargardt disease is supported by robust clinical and natural history data, with consistent benefits across patient subgroups and manageable side effects. Broad applicability and strong payer support are expected, with sufficient capital for commercialization.
Belite Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Tinlarebant, an oral therapy for Stargardt disease, showed a 36% reduction in lesion progression in phase III trials and is under priority FDA review with a PDUFA date in February. The drug has a strong safety profile, broad regulatory support, and commercial launch preparations are underway.
Belite Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
FDA and Japan reviews for Tinlarebant in Stargardt disease are progressing, with strong efficacy and safety data supporting broad use. Competitive analysis highlights Tinlarebant's advantages, and commercialization plans focus on genetic testing, awareness, and patient support.
Belite Bio price target raised to $234 from $220 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $234 from $220 and keeps an Outperform rating on the shares. The firm cites the company’s…
Belite Bio price target raised to $245 from $214 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $245 from $214 and keeps a Buy rating on the shares. The company announced the submission of a…
Belite Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Tinlarebant, an oral therapy for Stargardt disease and geographic atrophy, is under FDA priority review with a decision expected by February. The company anticipates broad patient eligibility, strong payer support, and manageable safety profile, while also advancing a global Phase III study in geographic atrophy.
Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1
Belite Bio (BLTE) announced the submission of a New Drug Application to the Ministry of Health, Labour, and Welfare in Japan for tinlarebant in Stargardt disease type 1. Tinlarebant is…
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targe...
Canaccord starts Belite Bio at Buy on additional post-IPO upside
Canaccord analyst Whitney Ijem initiated coverage of Belite Bio (BLTE) with a Buy rating and $303 price target The firm sees drivers for additional share upside over the near and…
Belite Bio initiated with a Buy at Canaccord
Canaccord initiated coverage of Belite Bio (BLTE) with a Buy rating and $303 price target
Belite Bio Transcript: Investor update
FDA has accepted the NDA for tinlarebant in Stargardt disease type 1, with priority review and a PDUFA date set for February 2027. Clinical data show significant efficacy and safety, and commercial preparations are advanced, targeting a large unmet need with robust physician and patient interest.
Belite Bio Slides: Investor update
Belite Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Belite Bio to Participate in Four Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeti...
Belite Bio to Host Virtual Commercial Day on September 2, 2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio price target raised to $206 from $201 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $206 from $201 and keeps an Overweight rating on the shares.
Belite Bio announces FDA acceptance, priority review of tinlarebant NDA
Belite Bio (BLTE) announced that the FDA has accepted and granted Priority Review designation of the NDA for tinlarebant for the treatment of Stargardt Disease Type 1. The FDA has…
Belite Bio price target raised to $214 from $200 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Belite Bio (BLTE) to $214 from $200 and keeps a Buy rating on the shares after the FDA accepted…
Belite Bio reports Q2 EPS (54c), consensus (78c)
As of June 30, the company had $279.9M in cash and cash equivalents, compared with $352.9M on December 31, 2025. “We continue to make significant strides in advancing tinlarebant in…
Belite Bio price target raised to $220 from $215 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $220 from $215 and keeps an Outperform rating on the shares. The firm updated the company’s…
Belite Bio price target raised to $270 from $266 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Belite Bio (BLTE) to $270 from $266 and keeps an Overweight rating on the shares. Belite Bio’s tinlarebant NDA…
Belite Bio price target raised to $206 from $201 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Belite Bio (BLTE) to $206 from $201 and keeps an Overweight rating on the shares after the company’s Q2 update. Following the…
Belite Bio Slides: Company presentation
Belite Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Belite Bio Earnings Call Transcript: Q2 2026
FDA accepted the NDA for tinlarebant with priority review, setting a PDUFA date of Feb 12, 2027. Q2 saw increased R&D and SG&A expenses, a net loss of $28.4M, and a strong cash position of $780M. Pediatric and geographic atrophy studies are advancing, with global regulatory filings planned.